Affiliation:
1. Universidade Federal de Mato Grosso, Brazil
2. Universidade do Estado de Mato Grosso, Brazil; Universidade Federal de Mato Grosso, Brazil
Abstract
ABSTRACT Objective: To analyze the use of ivermectin as COVID-19 prevention method by the population of Mato Grosso in 2020. Methods: This is a home-based survey, carried out between September and October 2020, in 10 pole cities of the socioeconomic regions of State. The use of ivermectin was evaluated through the question: “Did you take ivermectin to prevent COVID-19?”. Sociodemographic variables (sex, age group, education, family income), current work situation, being benefitted by government financial programs, as well as symptoms, seroprevalence of antibodies against SARS-CoV-2, and previous diagnosis of COVID-19 were evaluated. Prevalence and their associations were estimated using the chi-square test. Results: 4.206 individuals were evaluated for prevalence of ivermectin use; 58.3% of the individuals responded positively, this rate being higher in the municipalities of the western region of the state (66.6%). There was no significant difference between sexes, but the prevalence was higher among people aged 50–59 years (69.7%), who were white (66.5%), with complete higher education or more (68.8%) and higher family income (≥3 minimum wages-64.2%). The use of this drug was even higher among participants who considered their knowledge of the disease good or very good (65.0%), who reported having symptoms of COVID-19 (75.3%), and who had been previously diagnosed with the disease (91.2%). Conclusion: There was a high prevalence of use of ivermectin as a method to prevent covid-19 by the population of Mato Grosso, indicating the need for strategies to inform the population about the risks of off-label use of drugs and to combat the advertising of drugs that are ineffective against COVID-19.
Subject
Epidemiology,Public Health, Environmental and Occupational Health,General Medicine
Reference24 articles.
1. Infodemics and infodemiology: a short history, a long future;Zielinski C;Rev Panam Salud Publica,2021
2. Infodemia: excesso de quantidade em detrimento da qualidade das informações sobre a COVID-19;Garcia LP;Epidemiol Serv Saúde,2020
3. Ivermectin for preventing and treating COVID-19;Popp M;Cochrane Database Syst Rev,2021
4. Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19;Melo JRR;Cad Saúde Pública,2021
5. Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19 a randomized clinical trial;Naggie S;JAMA,2022